Grant: Alliance Grants
University of Toronto
$50,000.00
Integrating druggability and genetic variability of coronavirus genomes to inform drug discovery against COVID-19 and future pandemic threats_x000d_ _x000d_ _x000d_ _x000d_
EF 2020-21
Résumé
In partnership and after consultation with Cyclica, a Canadian biotech, we propose to use computer modelling to integrate genetic and structural data on the SARS-CoV-2 genome available from international public repositories. Using advanced structural bioinformatic tools, we will map genetic mutations from thousands of SARS-CoV-2 variants onto crystal structures of SARS-CoV-2 proteins to identify binding sites most amenable for the development of broad-spectrum inhibitors. We will then extend this exercise to coronavirus strains beyond SARS-CoV-2 to identify opportunities for the development of pan-coronavirus inhibitors. We will share all the knowledge generated on a Canadian online portal, which will become a valuable resource for drug discovery efforts at Cyclica, in Canada and around the world focused on the COVID-19 crisis. While the proposed work is a computational analysis of the COVID-19 and other coronavirus genomes, and is therefore not applied research, the knowledge generated will inform COVID-19 drug discovery efforts ongoing by our Alliance partner.
Programme
Alliance Grants
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
NSERC's Awards Data
Tel que publié
Application id
555329-2020
Name nom
Schapira, Matthieu
Department département
Pharmacology and Toxicology
Organization id
31
Institution établissement
University of Toronto
Province en
Ontario
Province fr
Ontario
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2020
Competition year année de concours
2020
Award amount
50000
Program id
ALLRP
Program name en
Alliance Grants
Program name fr
Subventions Alliance
Group en
Research partnerships programs
Group fr
Programmes de partenariat
Committee code
96
Committee name en
RPP Internal Decision Cttee
Committee name fr
Cté de décision interne - PPR
Area of application code
504
Area of application group en
Manufacturing processes and products
Area of application group fr
Procédés et produits industriels
Area of application en
Human pharmaceuticals
Area of application fr
Produits pharmaceutiques administrables à l'homme
Research subject code
9000
Research subject group en
Medical sciences
Research subject group fr
Sciences médicales
Research subject en
Medical sciences
Research subject fr
Sciences médicales
Installment
inst:1 - 1
Partie
1
Nb partie
1
Application title
Integrating druggability and genetic variability of coronavirus genomes to inform drug discovery against COVID-19 and future pandemic threats_x000d_
_x000d_
_x000d_
_x000d_
Keyword
NSERC
Application summary
In partnership and after consultation with Cyclica, a Canadian biotech, we propose to use computer modelling to integrate genetic and structural data on the SARS-CoV-2 genome available from international public repositories. Using advanced structural bioinformatic tools, we will map genetic mutations from thousands of SARS-CoV-2 variants onto crystal structures of SARS-CoV-2 proteins to identify binding sites most amenable for the development of broad-spectrum inhibitors. We will then extend this exercise to coronavirus strains beyond SARS-CoV-2 to identify opportunities for the development of pan-coronavirus inhibitors. We will share all the knowledge generated on a Canadian online portal, which will become a valuable resource for drug discovery efforts at Cyclica, in Canada and around the world focused on the COVID-19 crisis. While the proposed work is a computational analysis of the COVID-19 and other coronavirus genomes, and is therefore not applied research, the knowledge generated will inform COVID-19 drug discovery efforts ongoing by our Alliance partner.